Rosetta Genomics (Rosetta Genomics) EPS (Basic) : $-5.80 (TTM As of Jun. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics EPS (Basic)?

Rosetta Genomics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2017 was $-0.81. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2017 was $-5.80.

Rosetta Genomics's EPS (Diluted) for the three months ended in Jun. 2017 was $-0.81. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was $-5.80.

Rosetta Genomics's EPS without NRI for the three months ended in Jun. 2017 was $-0.45. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2017 was -5.44.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Rosetta Genomics EPS (Basic) Historical Data

The historical data trend for Rosetta Genomics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics EPS (Basic) Chart

Rosetta Genomics Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EPS (Basic)

Get a 7-Day Free Trial

-28.20

-16.08

-15.51

-13.79

-9.31

Rosetta Genomics Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17
EPS (Basic)	Get a 7-Day Free Trial															-2.40	-1.95	-2.28	-2.71	-0.81

Rosetta Genomics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Rosetta Genomics's Basic EPS for the fiscal year that ended in Dec. 2016 is calculated as

Basic EPS (A: Dec. 2016 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.233	-	0)	/	1.743
	=	-9.31

Rosetta Genomics's Basic EPS for the quarter that ended in Jun. 2017 is calculated as

Basic EPS (Q: Jun. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.071	-	0)	/	2.546
	=	-0.81

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.80

Rosetta Genomics (OTCPK:ROSGQ) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Rosetta Genomics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Plaut Street, Science Park, Rehovot, ISR, 76706

Website

http://www.rosettagenomics.com

Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.

Executives

Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd.	10 percent owner	C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458

Rosetta Genomics (Rosetta Genomics) Headlines

From GuruFocus

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

By gurufocus • 12-09-2008